What Is The Current and Historic Market Size Analysis Of The Erythropoietin EPO Market?
The erythropoietin epo market has seen considerable growth due to a variety of factors.
• In the past few years, the erythropoietin (EPO) market has seen fast-paced growth. The market size is expected to surge from $17.29 billion in 2024 to $19.25 billion in 2025, with a compound annual growth rate (CAGR) of 11.4%.
This rampant growth during the historic period can be traced back to factors such as enhanced patient education and awareness, mergers in the pharmaceutical industry, health insurance reimbursement policies, market proliferation and rising demand, the expiration of patents and the introduction of biosimilars.
What are the Market Size and Expected Growth Rates for the Erythropoietin EPO Market?
The erythropoietin epo market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, a swift expansion is anticipated in the erythropoietin (EPO) market. This will rocket it to an estimated worth of $30.92 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 12.6%.
The growth during this forecasted period can be credited to factors such as market rivalry and the effect of biosimilar, projected disease prevalence rates, changes in healthcare policy and reimbursement, the expansion of emerging markets, and the concentration on clinical trials and research. Significant trends within this period are expected to encompass supply chain management, global enlargement and emerging markets, patient enlightenment and awareness, reimbursement strategies, as well as market consolidation and mergers.
Which Key Drivers Are Propelling The Erythropoietin EPO Market's Growth?
The escalating number of chronic kidney disease cases is expected to fuel the need for the erythropoietin market in the forthcoming years. The surge in chronic kidney disease cases necessitates the use of erythropoietin, essential in the production of red blood cells which boost immunity. For instance, per data from the Centers for Disease Control, a US federal agency, in 2023, around 14% of U.S. adults, representing roughly 35.5 million people, are projected to suffer from chronic kidney disease (CKD). Therefore, the increase in chronic kidney disease frequency heightens the need for erythropoietin, consequently propelling market revenues.
What Are The Key Segments Within The Global Erythropoietin EPO Market?
The erythropoietin (EPO) market covered in this report is segmented –
1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products
2) By Drug Class: Biologist, Biosimilar
3) By Application: Cancer, Hematology, Renal Diseases, Neurology, Other Applications
Subsegments:
1) By Epoetin-Alfa: Epoetin-Alfa, Epoetin-Alfa Biosimilars
2) By Epoetin-Beta: Epoetin-Beta, Epoetin-Beta Biosimilars
3) By Darbepoetin-Alfa: Darbepoetin-Alfa, Darbepoetin-Alfa Biosimilars
4) By Other Products: Peginesatide, Other Novel EPO Products
Pre-Book The Erythropoietin EPO Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Erythropoietin EPO Industry?
Prominent corporations in the erythropoietin market are emphasizing the development and launch of oral drugs as more user-friendly options compared to traditional injection-based treatments. The objective is to enhance patient convenience, adherence to medication and offer flexible treatment options, especially for those dealing with chronic illnesses such as anemia associated with chronic kidney disease (CKD). In February 2023, for example, the renowned UK-based pharmaceutical and biotechnology firm, GlaxoSmithKline (GSK), introduced Jesduvroq (daprodustat) tablets to the market. These tablets serve to raise erythropoietin levels, enabling the effective management of anemia in CKD patients by maintaining hemoglobin levels in a target range. Jesduvroq is designed to present a more suitable option for patients than injectable therapies, intending to enhance comfort, medication adherence, and flexible treatment for those undergoing dialysis.
Who Are the Key Players In The Erythropoietin EPO Market?
Major companies operating in the erythropoietin (EPO) market include:
• Amgen Inc.
• Roche Holding AG
• Pfizer Inc.
• Merck & Co.
• Teva Pharmaceutical Industries Ltd.
• 3SBio Inc.
• Celltrion Inc.
• Intas Pharmaceuticals Ltd.
• Boehringer Ingelheim GmbH
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Reliance Life Sciences Pvt. Ltd.
• Biocon Limited
• Chugai Pharmaceutical Co.
• Kyowa Kirin Co. Ltd.
• Apotex Inc.
• CJ Healthcare Corp.
• STADA Arzneimittel AG
• Hospira Inc.
• Sandoz International GmbH
• Torrent Pharmaceuticals Ltd.
• LG Life Sciences Ltd.
• Sanofi S.A.
• Bayer AG
• Hikma Pharmaceuticals.
What Are The Regional Insights Into The Erythropoietin EPO Market?
North America was the largest region in the erythropoietin (EPO) market in 2024. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
